Sars-Cov-2 Infection Does Not Worsen the Course of Inflammatory Bowel Disease in the Long Term

Background and aim: The long-term outcome of inflammatory bowel disease (IBD) patients after SARS-CoV-2 infection is under investigation. In a prospective, single-center study, we aimed to assess whether a recent SARS-CoV-2 infection increases the risk of IBD relapse within 12 months. Material(s) and Method(s): From March to April 2021, all IBD patients with recent (<2 months) SARS-CoV-2 infection (Cases) were enrolled. For each enrolled Case, 4 IBD Controls with no history of infection were considered. Clinical course of IBD was recorded for 12 months. Inclusion criteria: a) well-defined diagnosis of IBD;b) age >=18 and <=85 years;c) 12-months follow-up;d) consent. Exclusion criteria: a) incomplete data;b) SARS-CoV-2 infection after enrollment. Additional inclusion criteria: a) recent SARS-CoV-2 infection for Cases;b) no history of SARS-CoV-2 infection for Controls. Data were expressed as median [range]. Normal distribution of continuous variables was assessed through the Kolmogonov-Smirnov test. Statistical analysis included Student-t Test, Mann-Whitney u-test, 2 test, multivariate logistic regression model (OR [95% CI]), Kaplan- Meier curves, as appropriate. Result(s): During the study period, 143 IBD patients were enrolled. The analysis included 118 patients (22 met the exclusion criteria, 3 lost at follow-up): 29 (24.6%) Cases, 89 (75.4%) Controls. Demographic and clinical characteristics were comparable between groups. During the 12-months study, the frequency of IBD relapse was comparable between Cases and Controls (8 [27%] vs 19 [21%];p=0.65). At univariate analysis, SARS-CoV-2 infection was not a risk factor for IBD relapse within 12-months (1.5 [0.6-3.9];p=0.34). At multivariate analysis, IBD activity at baseline was the only risk factor for relapse (3.2 [1.1-9.1];p=0.03). Kaplan-Meier curves showed that survival from IBD relapse was comparable between Cases and Controls (p=0.33). Conclusion(s): In a prospective 12-months study, a recent SARSCoV- 2 infection did not increase the risk of clinical relapse of IBD in the long term.Copyright © 2023. Editrice Gastroenterologica Italiana S.r.l.

COVID-19 Lockdown Effects on a Highly Contaminated Coastal Site: The Mar Piccolo Basin of Taranto

The COVID-19 pandemic has had a dramatic socio-economic impact on mankind;however, the COVID-19 lockdown brought a drastic reduction of anthropic impacts on the environment worldwide, including the marine–coastal system. This study is concentrated on the Mar Piccolo basin of Taranto, a complex marine ecosystem model that is important in terms of ecological, social, and economic activities. Although many numerical studies have been conducted to investigate the features of the water fluxes in the Mar Piccolo basin, this is the first study conducted in order to link meteo-oceanographic conditions, water quality, and potential reduction of anthropic inputs. In particular, we used the model results in order to study the response of the Mar Piccolo basin to a drastic reduction in the leakage of heavy metal IPAs from industrial discharges during the two months of the mandated nationwide lockdown. The results show the different behavior of the two sub-basins of Mar Piccolo, showing the different times necessary for a reduction in the concentrations of heavy metals even after a total stop in the leakage of heavy metal IPAs. The results highlight the high sensitivity of the basin to environmental problems and the different times necessary for the renewal of the water in both sub-basins. © 2023 by the authors.

SARS-CoV-2 Igg seroprevalence in IBD patients treated with biologics: first vs. second pandemic wave in a prospective study.

OBJECTIVE: In a prospective study, SARS-CoV-2 IgG seroprevalence was assessed during the second pandemic wave (W2) in a cohort of Inflammatory Bowel Disease (IBD) patients using biologics. The secondary aim was to compare, in the same cohort, the frequency of seropositivity and of COVID-19 during the second vs. the first (W1) wave. PATIENTS AND METHODS: From November 2020 to March 2021, SARS-CoV-2 IgG seropositivity and the prevalence of COVID-19 were assessed in a cohort of IBD patients using biologics already studied at W1. INCLUSION CRITERIA: age ≥ 18 years; diagnosis of IBD; follow-up; written consent. EXCLUSION CRITERIA: SARS-CoV-2 vaccination. Risk factors for infection, compatible symptoms, history of infection or COVID-19, nasopharyngeal swab test were recorded. Data were expressed as median [range]. The χ2 test, Student's t-test, logistic regression analysis was used. RESULTS: IBD cohort at W1 and W2 included 85 patients: 45 CD (52.9%), 40 UC (47.1%). When comparing the same 85 patients at W2 vs. W1, a higher SARS-CoV-2 seroprevalence at W2 was at the limit of the statistical significance (9.4% vs. 2.3%; p=0.05). The prevalence of COVID-19 at W2 vs. W1 was 3.5% (3/85) vs. 0% (0/85) (p=0.08). Contacts with COVID-19 patients and symptoms compatible with COVID-19 were more frequent at W2 vs. W1 (18.8 % vs. 0%; p=0.0001; 34.1% vs. 15.3%; p=0.004). At W2, history of contacts and new onset diarrhea were more frequent in seropositive patients [4/8 (50%) vs. 12/77 (15.6%); p=0.01 and 4/8 (50%) vs. 2/77 (2.6%); p=0.0001]. At W2, the risk factors for seropositivity included cough, fever, new onset diarrhea, rhinitis, arthromyalgia, dysgeusia/anosmia at univariate (p<0.05), but not at multivariate analysis. History of contacts was the only risk factor for seropositivity at univariate (p=0.03), but not at multivariate analysis (p=0.1). CONCLUSIONS: During W2, characterized by a high viral spread, IBD and biologics appeared not to increase the prevalence of SARS-CoV-2 infection or COVID-19 disease. New onset diarrhea mimicking IBD relapse may be observed in patients with SARS-CoV-2 infection.

Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.

OBJECTIVE: Treatments used in Inflammatory Bowel Disease (IBD) have been associated with enhanced risk of viral infections and viral reactivation, however, it remains unclear whether IBD patients have increased risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. The aim of the study was to examine the prevalence of SARS-CoV-2 IgG positivity in IBD patients followed at our referral center. The role of treatments for IBD and risk factors for infection were also evaluated. PATIENTS AND METHODS: In a prospective study, all IBD patients followed at our referral centre between May 27th and July 21st, 2020 and fulfilling the inclusion criteria were tested for SARS-CoV-2 IgG. Specific IgG antibodies were evaluated by a commercial ELISA kit and SARS-CoV-2 nasopharyngeal swab was performed in seropositive patients. RESULTS: Two-hundred and eighteen patients, 128 Crohn's disease (CD) and 90 Ulcerative colitis (UC) [age 44, (19-77) years; ongoing biologics in 115 (52.7%)] were enrolled. No patient had major SARS-CoV-2-related symptoms. SARS-CoV-2 IgG were detected in 3 out of 218 (1.37%) patients with IBD (2 CD and 1 UC), all on biologics (2.6%). In all of the 3 seropositive patients, the nasopharyngeal swab was negative. There was no relationship between SARS-CoV-2 seroprevalence and the demographic/clinical characteristics of IBD patients. In contrast, history of recent travel was more frequent in the SARS-CoV-2 seropositive patients (2/3; 66.6%) than in SARS-CoV-2 seronegative patients [7/215 (3.25%); p<0.0001]. CONCLUSIONS: The prevalence of SARS-CoV-2 IgG seropositivity in IBD patients appears to be comparable to the non-IBD population and not influenced by ongoing treatments. Risk factors for infection common to the general non-IBD population should be considered when managing patients with IBD.